NBRV Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 1.63%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Nabriva Therapeutics Insider Trading History Chart

Nabriva Therapeutics Share Price & Price History

^$0.00

+0.30 (1.20%)

As of 11/21/2024 01:00 AM ET

Days: 30 | 90 | 365

Let’s be blunt

From DTI | Ad

Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)!

Check out the $100 Challenge now

Nabriva Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/1/2022	Charles A Rowland Jr	Director	Sell	8,496	$0.17	$1,444.32	15,277
12/28/2021	Theodore R Schroeder	CEO	Buy	100,000	$0.57	$57,000.00
12/27/2021	J. Christopher Naftzger	General Counsel	Buy	7,000	$0.59	$4,130.00

Buffett Dumps $982 Million in BofA Stock—What Does He Know?

From Genesis Gold Group | Ad

Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.

Get your FREE, no-obligation Wealth Protection Guide now

SEC Filings (Institutional Ownership Changes) for Nabriva Therapeutics (NASDAQ:NBRV)

0.27% of Nabriva Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Nabriva Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/14/2023	Susquehanna International Group LLP	22,294	$41K	0.0%	N/A	0.073%
12/2/2022	Values First Advisors Inc.	25,891	$54K	0.0%	-40.8%	0.085%
5/16/2022	Frazier Life Sciences Management L.P.	425,650	$0.18M	0.0%	N/A	0.070%
2/14/2022	GSA Capital Partners LLP	357,481	$0.21M	0.0%	N/A	0.066%
11/16/2021	Two Sigma Securities LLC	39,936	$48K	0.0%	N/A	0.007%
11/5/2021	Advisor Group Holdings Inc.	26,500	$32K	0.0%	+5,200.0%	0.005%
9/3/2021	Parametric Portfolio Associates LLC	41,079	$55K	0.0%	+144.8%	0.008%
8/16/2021	State Street Corp	183,336	$0.25M	0.0%	+70.6%	0.037%
8/13/2021	Renaissance Technologies LLC	869,390	$1.17M	0.0%	+665.3%	0.176%
8/1/2021	Clear Creek Financial Management LLC	20,050	$27K	0.0%	N/A	0.004%
5/19/2021	Virtu Financial LLC	31,186	$52K	0.0%	+41.4%	0.009%
5/19/2021	Squarepoint Ops LLC	156,623	$0.26M	0.0%	N/A	0.044%
5/18/2021	Jane Street Group LLC	47,061	$78K	0.0%	N/A	0.019%
5/14/2021	Dimensional Fund Advisors LP	35,302	$59K	0.0%	+67.2%	0.014%
5/13/2021	Renaissance Technologies LLC	113,601	$0.19M	0.0%	-66.8%	0.045%
3/8/2021	Dimensional Fund Advisors LP	21,112	$51K	0.0%	-91.5%	0.014%
2/25/2021	Dimensional Fund Advisors LP	21,112	$51K	0.0%	-91.5%	0.014%
2/24/2021	Virtu Financial LLC	22,060	$53K	0.0%	N/A	0.015%
2/13/2021	Clear Creek Financial Management LLC	20,050	$48K	0.0%	N/A	0.013%
2/11/2021	Frazier Management LLC	425,650	$1.03M	0.1%	-90.0%	0.282%
2/10/2021	Renaissance Technologies LLC	342,360	$0.83M	0.0%	+1,025.0%	0.227%
2/9/2021	Wells Fargo & Company MN	14,464	$35K	0.0%	-92.8%	0.010%
2/5/2021	Aisling Capital Management LP	191,028	$0.46M	0.1%	-90.0%	0.127%
2/4/2021	GSA Capital Partners LLP	50,549	$0.12M	0.0%	N/A	0.034%
1/21/2021	Kestra Private Wealth Services LLC	35,174	$88K	0.0%	-94.5%	0.023%
11/13/2020	Morgan Stanley	361,377	$0.19M	0.0%	-13.3%	0.018%

Data available starting January 2016

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.